Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.
about
Exposure of neutralizing epitopes in the carboxyl-terminal domain of TcdB is altered by a proximal hypervariable region.Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.Bezlotoxumab: First Global Approval.Emerging monoclonal antibodies against Clostridium difficile infection.Bezlotoxumab for the prevention of Clostridium difficile recurrence.Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.Use of a neutralizing antibody helps identify structural features critical for binding of Clostridium difficile toxin TcdA to the host cell surface.The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection.Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection.Bezlotoxumab.Clostridium difficile Toxoid Vaccine Candidate Confers Broad Protection against a Range of Prevalent Circulating Strains in a Nonclinical Setting.Antibiotic resistance: a rundown of a global crisis
P2860
Q35172641-E77DE4AA-12A0-42B3-A7AD-5ED70CD0C36FQ36609408-B075429D-F50D-4FC7-A040-D4A35A68A661Q38597041-9170DF67-9B4F-466F-AFBC-992D47272086Q39025270-4229F395-BD07-4448-864B-154EBFA7F47FQ39168914-1D9D976F-945C-47A8-BA9A-B7DDF922CEBEQ40095035-C8795479-DD5E-422A-A743-59E6BBDCB7CEQ40125340-B359A42D-BF43-4132-B6E7-A9ED665B60E9Q40135481-F9F97F4D-12F0-4976-800C-3E0AFF18F1ABQ40499019-D11BC663-E9C7-4FC4-B13B-59E0CF56655CQ49201152-E3258E37-263B-477C-A3E9-C47F47ADF666Q53762105-283CB3C3-3E46-4FAA-9E52-389830234DC5Q54239070-3761C102-FF6D-4A7A-9D1E-723B2568C2EEQ57816209-CE0E6038-6B80-44F8-8D88-17C731594721
P2860
Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Broad coverage of genetically ...... lization and epitope modeling.
@ast
Broad coverage of genetically ...... lization and epitope modeling.
@en
type
label
Broad coverage of genetically ...... lization and epitope modeling.
@ast
Broad coverage of genetically ...... lization and epitope modeling.
@en
prefLabel
Broad coverage of genetically ...... lization and epitope modeling.
@ast
Broad coverage of genetically ...... lization and epitope modeling.
@en
P2093
P2860
P356
P1476
Broad coverage of genetically ...... lization and epitope modeling.
@en
P2093
Alex G Therien
Edward DiNunzio
Fred Racine
Lorraine D Hernandez
Nichelle Hairston
Nicholas J Murgolo
Payal R Sheth
P2860
P304
P356
10.1128/AAC.04433-14
P407
P577
2014-12-01T00:00:00Z